ArticlePloS one2025
Global burden of Alzheimer's disease and other dementias attributable to smoking in 204 countries and territories, 1990-2021.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The Burden of Alzheimer's Disease and Other Dementias Attribute to Metabolic Risks in Western Europe From 1990 to 2023.Diabetes, obesity & metabolism · 2026Article
- Rodent Models of Alzheimer's Disease: Bridging the Translational Gap Through Systems-Level Integration.Biomedicines · 2026Review
- Tobacco use and cognitive impairment: A bibliometric analysis of research trends and knowledge structure.Tobacco induced diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlzheimer's disease and other dementias (ADD) are significant global public health challenges. Smoking is a clearly established modifiable risk factor for dementia.
objectiveThis study aims to systematically elucidate the burden of ADD attributable to smoking from 1990 to 2021.
methodsWe obtained data on Disability Adjusted Life Years (DALYs) and age-standardized DALYs rate (ASDRs) associated with ADD attributable to smoking from the Global Burden of Disease (GBD) database for the years 1990-2021. These data were disaggregated by gender, age, sociodemographic index (SDI), and region. Temporal trends in the burden of smoking-induced ADD were examined by calculating the average annual percentage changes.
resultsFrom 1990-2021, global ASDR of smoking-attributed ADD declined 21.3% (EAPC = -0.88%) while DALYs increased 93% to 1.53 million. Females showed faster ASDR decline (EAPC = -1.50% vs male -0.73%). DALYs peaked at 65-85 years with accelerated crude rates post-75. Regionally, East Asia (611760.52, 262060.15-1401979.1), Western Europe (184593.67, 78898.94-420812.86), High-income North America (164283.74, 72809.79-373190.34) had highest 2021 DALYs; East Asia (29.95, 12.67-68.10), High income North America (23.32, 10.39-52.46), Tropical Latin America (20.81, 9.05-48.62) had highest ASDR. Nationally, China, United States of America and Lebanon led burdens. Steepest declines occurred in Mexico (EAPC = -3.14%), South Africa (-3.14%), and Sri Lanka (-2.84%). ASDR correlated with SDI (r = 0.44, p < 0.001) showing bimodal peaks at SDI = 0.5 and 0.8. Frontier analysis revealed peak heterogeneity in Alzheimer's disease ASDR around SDI 0.75, with the largest effectiveness disparities observed primarily in Middle-High SDI countries, indicating urgent needs for targeted health interventions despite declining trends in high-SDI nations.
conclusionDespite declining dementia ASDR, global DALYs rose absolutely. The burden disproportionately impacted older populations, males, and high-middle-income nations. Mitigation requires context-adapted interventions including enhanced tobacco control, equitable healthcare access, and targeted health education.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.